Timber Pharmaceuticals, Inc. (TMBR)
|Net Income (ttm)||-15.26M|
|Trading Day||May 7|
|Day's Range||1.07 - 1.37|
|52-Week Range||0.38 - 5.69|
- Edward J. Sitar appointed as Lead Independent Director of the Board -
It's never a dull day on the Reddit Penny Stocks subreddit and we're checking in to see what's being talked about the most today. The post 5 Reddit Penny Stocks Seeing the Most Chatter Thursday appeared...
Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings
Basking Ridge, NJ, April 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (NYSE American: TMBR) ("Timber” or the "Company"), a biopharmaceutical company focused on the devel...
50% of patients in the Phase 2b CONTROL study have now been randomized despite COVID-19 disruptions in the trial marketplace
Timber Pharmaceuticals' Development Partner, AFT Pharmaceuticals, Enters into Licensing Agreement for Pascomer® (TMB-...
- Extension of agreement with AFT Pharmaceuticals grants Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe -
- Study is Evaluating TMB-001 (Topical Isotretinoin) in Subtypes of Rare Genetic Keratinization Disorder
Timber Pharmaceuticals spiked more than 75% in trading today following a virtual life sciences conference this week. Trading volume in TMBR stock was up more than 1600% on the day.
Timber Pharmaceuticals Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference
WOODCLIFF LAKE, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the de...
These penny stocks are companies that have a crucial year ahead in terms of industry turnaround or company specific product development. The post 7 Penny Stocks In a Make-or-Break Year appeared first on...
Dr. Mendelsohn has 20+ Years' Experience in Clinical Development and Medical Affairs
Timber Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for TMB-003 for the Treatment of Systemic Scler...
Timber Expects to Submit Investigational New Drug (IND) Application to the FDA in 2022
Call to be held on Thursday, December 17th at 11:00am EST
Presentation on Tuesday December 15th at 10:40am EST
Biopharmx Corp shares spiked higher Tuesday morning after the company announced its Phase 2b trial of BPX-04 for Populopustular Rosacea has met both primary and secondary endpoints and was well tolerated.
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical dermatology company, focused on the development and commercialization of treatments for orphan dermatologic diseases. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
|Stock Exchange |
|Ticker Symbol |